SPYH:XETRA:XETRA-SPDR® MSCI Europe Health Care UCITS ETF (EUR)

ETF | Others |

Last Closing

USD 213.6

Change

+1.80 (+0.85)%

Market Cap

USD 0.66B

Volume

506.00

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

NA

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-01-08 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
XM1D:XETRA Xtrackers MSCI Japan UCITS ETF..

-0.08 (-0.14%)

USD 446.30B
LCUJ:XETRA Lyxor Core MSCI Japan (DR) UCI..

-0.04 (-0.22%)

USD 191.96B
PRAJ:XETRA Amundi Index Solutions - Amund..

-0.06 (-0.22%)

USD 177.46B
PR1J:XETRA Amundi Prime Japan UCITS ETF D..

-0.04 (-0.12%)

USD 177.46B
XDJP:XETRA Xtrackers Nikkei 225 UCITS ETF..

+0.13 (+0.52%)

USD 157.79B
JARI:XETRA Amundi Index Solutions - Amund..

-0.42 (-0.91%)

USD 104.21B
8R80:XETRA Amundi Index Solutions - Amund..

-1.58 (-1.10%)

USD 102.09B
UIM5:XETRA UBS (Lux) Fund Solutions - MSC..

-0.05 (-0.09%)

USD 85.64B
EUNL:XETRA iShares Core MSCI World UCITS ..

+0.08 (+0.07%)

USD 84.07B
SXR8:XETRA iShares Core S&P 500 UCITS ETF..

+0.82 (+0.13%)

USD 80.38B

ETFs Containing SPYH:XETRA

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 2.10% 84% B 79% B-
Dividend Return N/A N/A N/A N/A N/A
Total Return 2.10% 84% B 79% B-
Trailing 12 Months  
Capital Gain 1.74% 21% F 28% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 1.74% 18% F 25% F
Trailing 5 Years  
Capital Gain 32.70% 61% D- 63% D
Dividend Return N/A N/A N/A N/A N/A
Total Return 32.70% 57% F 58% F
Average Annual (5 Year Horizon)  
Capital Gain 9.19% 62% D 61% D-
Dividend Return 9.19% 61% D- 59% D-
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 8.19% 70% C- 76% C+
Risk Adjusted Return 112.17% 96% N/A 96% N/A
Market Capitalization 0.66B 70% C- 62% D

Annual Financials (EUR)

Quarterly Financials (EUR)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

What to not like:

There is nothing we particularly dislike